Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. Research shows that the drug activates the cannabinoid neurotransmitter system (which protects the brain), and this stimulates the cholinergic system (which controls memory and learning) by increasing the synthesis of acetylcholine (a neurotransmitter in the brain that controls memory and learning). These results open up a promising therapeutic approach.